Efficacy of linezolid compared to vancomycin in an experimental model of pneumonia induced by methicillin-resistant Staphylococcus aureus in ventilated pigs

Critical Care Medicine

Volumn 40, Issue 1, 2012, Pages 162-168

  Martinez Olondris, Pilar ^a,c   Rigol, Montserrat ^b,c   Soy, Dolors ^a,c   Guerrero, Laura ^a,c   Agusti, Carlos ^a,c   Quera, Maria Angels ^b   Li Bassi, Gianluigi ^a   Esperatti, Mariano ^a,c   Luque, Nestor ^a,c   Liapikou, Manto ^a   Filella, Xavier ^b   Marco, Francesc ^b   De La Bellacasa, Jordi Puig ^b   Torres, Antoni ^a,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Animal model; Linezolid; Methicillin resistant Staphylococcus aureus; Vancomycin; Ventilator associated pneumonia

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 8; LINEZOLID; TUMOR NECROSIS FACTOR ALPHA; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTIFICIAL VENTILATION; BACTERIUM CULTURE; BRONCHOSCOPY; COLONY FORMING UNIT; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG PENETRATION; DRUG TISSUE LEVEL; EXPERIMENTAL PIG; HISTOPATHOLOGY; INOCULATION; LUNG LAVAGE; LUNG LOBE; LUNG PARENCHYMA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PASTEURELLA MULTOCIDA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESPIRATORY TRACT INTUBATION; STAPHYLOCOCCAL PNEUMONIA; STEADY STATE; TREATMENT DURATION;

ACETAMIDES; ANIMALS; ANTI-BACTERIAL AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODELS, ANIMAL; INTERLEUKIN-6; INTERLEUKIN-8; LUNG; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OXAZOLIDINONES; PNEUMONIA, STAPHYLOCOCCAL; PNEUMONIA, VENTILATOR-ASSOCIATED; RESPIRATION, ARTIFICIAL; SWINE; TUMOR NECROSIS FACTOR-ALPHA; VANCOMYCIN;

EID: 84055160924     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31822d74a2     Document Type: Article

References (38)

1. National Nosocomial Infections Surveillance (NNIS) System report, data summary from October 1986 through April 1998. Atlanta, GA: Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, 1998
2. Cosgrove SE, Sakoulas G, Perencevich EN, et al: Comparison of mortality associated with methicillin-resistant and methicillinsusceptible Staphylococcus aureus bacteremia: A meta-analysis. Clin Infect Dis 2003; 36:53-59
3. Vincent JL, Bihari DJ, Suter PM, et al: The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995; 274: 639-644
4. Graffunder EM, Venezia RA: Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother 2002; 49:999-1005
5. Fridkin SK, Hill HA, Volkova NV, et al: Temporal changes in prevalence of antimicrobial resistance in 23 US hospitals. Emerg Infect Dis 2002; 8:697-701
6. Bodi M, Ardonuy C, Rello J: Impact of Grampositive resistance on outcome of nosocomial pneumonia. Crit Care Med 2001; 29:82-86
7. Boucher HW, Corey GR: Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008; 46:S344-S349
8. Kollef MH: Limitations of vancomycin in the management of resistant Staphylococcal infections. Clin Infect Dis 2007; 45: S191-S195
9. Wunderink RG, Mendelson MH, Somero MS, et al: Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus. Chest 2008; 134: 1200-1207
10. Rubinstein E, Cammarata SK, Oliphant TH, et al: Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32:402-412
11. Cruciani M, Gatti G, Lazzarini L, et al: Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996; 38:865-869
12. Lamer C, de Beco V, Soler P, et al: Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993; 37:281-286
13. Moise PA, Schentag JJ: Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int J Antimicrob Agents 2000; 16(Suppl 1): S31-S34
14. Baughman RP, Kerr MA: Ventilator-associated pneumonia patients who do not reduce bacteria from the lungs have a worse prognosis. J Intensive Care Med 2003; 18: 269-274
15. Diekema DI, Jones RN: Oxazolidinones: A review. Drugs 2000; 59:7-16
16. Plosker GL, Figgitt DP: Linezolid: A pharmacoeconomic review of its use in serious Gram-positive infections. Pharmacoeconomics 2005; 23:945-964
17. Boselli E, Breilh D, RimmeléT, et al: Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med 2005; 33: 1529-1533
18. Conte JE Jr, Golden JA, Kipps J, et al: Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002; 45: 1475-1480
19. Wunderink RG, Cammarata SK, Oliphant TH, et al: Linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia: Continuation of a randomized, double-blind, multicenter study. Clin Ther 2003; 25:980-992
20. Wunderink RG, Rello J, Cammarate SK, et al: Linezolid versus Vancomycin. Chest 2003; 12:1789-1797
21. Kunkel M, et al: "Linezolid vs vancomycin in the treatment of nosocomial pneumonia proven due to methicillin-resistant Staphylococcus aureus" IDSA 2010; abstract LB-49
22. Luna CM, Bruno DA, García-Morato J, et al: Effect of linezolid compared with glycopeptides in methicillin-resistant Staphylococcus aureus severe pneumonia in piglets. Chest 2009; 135:1564-1571
23. van Dalen R, Vree TB: Pharmacokinetics of antibiotics in critically ill patients. Intensive Care Med 1990; 16(Suppl 3):S235-S238
24. Pea F, Porreca L, Baraldo M, et al: High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. J Antimicrob Chemother 2000; 45:329-335
25. Mouton JW, Dudley MN, Cars O, et al: Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Int J Antimicrob Agents 2002; 19: 355-358
26. Moise PA, Forrest A, Bhavnani SM, et al: Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm 2000; 57(Suppl 2):S4-S9
27. del Mar Fernández de Gatta Garcia MM, Revilla N, Calvo MV, et al: Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients. Intensive Care Med 2007; 33: 279-285
28. Martinez-Olondris P, Sibila O, Agustí C, et al: An experimental model of pneumonia induced by methicillin-resistant Staphylococcus aureus in ventilated piglets. Eur Resp J 2010; 36:901-906
29. Sibila O, Luna CM, Agustí C, et al: Effects of glucocorticoids in ventilated piglets with severe pneumonia. Eur Respir J 2008; 32: 1037-1046
30. Rybak M, Lomaestro B, Rotschafer JC, et al: Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America and the Society of Infectious Disease Pharmacists. Am J Health Sys Pharm 2009; 66:82-98
31. el-Ebiary M, Torres A, González J, et al: Quantitative cultures of endotracheal aspirates for the diagnosis of ventilator-associated pneumonia. Am Rev Respir Dis 1993; 148:1552-1557
32. Balows A, Hausler WJJ (Eds): Manual of Clinical Microbiology. Fifth Edition. Washington, DC, American Society for Microbiology, 1991
33. Marquette CH, Copin MC, Wallet F, et al: Diagnostic tests for pneumonia in ventilated patients: Prospective evaluation of diagnostic accuracy using histology as a diagnostic gold standard. Am J Respir Crit Care Med 1995; 151:1878-1888
34. Guerrero L, Martínez-Olondris P, Rigol M, et al: Development and validation of an high-performance liquid chromatography method to determine linezolid concentrations in pig pulmonary tissue. Clin Chem Lab Med 2010; 48:391-398
35. Guerrero L, Sarasa M, Ló pez Y, et al: [Measuring linezolid in biological fluids using high-efficiency liquid chromatography]. Farm Hosp 2010; 34:27-31
36. Choi EY, Huh JW, Lim CM, et al: Relationship between the MIC of vancomycin and clinical outcome in patients with MRSA nosocomial pneumonia. Intensive Care Med 2011; 37:639-647
37. Haque NZ, Zuniga LC, Peyrani P, et al: Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or healthcare-associated pneumonia. Chest 2010; 138:1356-1362
38. Rayner CR, Forrest A, Meagher AK, et al: Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 2004; 42:1411-1423